These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35817320)

  • 1. Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.
    Huang H; Miao J; Xiao X; Hu J; Zhang G; Peng Y; Lu S; Liang Y; Huang S; Han F; Deng X; Zhao C; Wang L
    Radiother Oncol; 2022 Oct; 175():1-9. PubMed ID: 35817320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter to the editor of radiotherapy and oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study." by Huang et al.
    Sarode GS; Sarode SC; Anand R
    Radiother Oncol; 2022 Dec; 177():252. PubMed ID: 36334695
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study." by Huang et al.
    Huang H; Miao J; Zhao C; Wang L
    Radiother Oncol; 2022 Dec; 177():253. PubMed ID: 36334696
    [No Abstract]   [Full Text] [Related]  

  • 4. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Zhao DW; Fan WJ; Fang XM; Luo YR; Wei J; Chen NX; Zhang XX; Liu G; Li JF; Zang X; Li M; Meng L; Ma L
    Radiother Oncol; 2022 Jul; 172():91-98. PubMed ID: 35584742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.
    Kam MK; Leung SF; Zee B; Chau RM; Suen JJ; Mo F; Lai M; Ho R; Cheung KY; Yu BK; Chiu SK; Choi PH; Teo PM; Kwan WH; Chan AT
    J Clin Oncol; 2007 Nov; 25(31):4873-9. PubMed ID: 17971582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of the parotid-sparing effect of intensity-modulated radiotherapy (IMRT) in early stage nasopharyngeal carcinoma: A 15-year follow-up of a randomized prospective study of IMRT versus two-dimensional radiotherapy.
    Poon DMC; Kam MKM; Johnson D; Mo F; Tong M; Chan ATC
    Head Neck; 2021 Jun; 43(6):1711-1720. PubMed ID: 33576030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of submandibular glands protection on xerostomia as monitored by diffusion-weighted imaging in nasopharyngeal carcinoma patients.
    Zhao D; Fan W; Jiang H; Meng L; Cai B; Zhang X; Yu W; Zhao L; Ma L
    Strahlenther Onkol; 2024 May; 200(5):377-388. PubMed ID: 37955647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis.
    Sommat K; Hussain A; Ong WS; Yit NLF; Khoo JBK; Soong YL; Wee JTS; Fong KW; Tan TWK
    Radiother Oncol; 2019 Sep; 138():149-157. PubMed ID: 31265972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study.
    Fan WJ; Teng F; Luo YR; Yu W; Zhang Q; Lu YP; Ma L
    Strahlenther Onkol; 2020 Jun; 196(6):530-541. PubMed ID: 32025803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study.
    Madhwapathy KS; Manur J
    J Cancer Res Ther; 2024 Jul; 20(5):1400-1405. PubMed ID: 39412906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dynamic observation on the short-term change of xerostomia after intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma].
    Li Y; Zhao C
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 50(1):33-7. PubMed ID: 25764925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer.
    Marucci L; Marzi S; Sperduti I; Giovinazzo G; Pinnarò P; Benassi M; Strigari L
    Head Neck; 2012 Mar; 34(3):328-35. PubMed ID: 21400632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.
    Richards TM; Hurley T; Grove L; Harrington KJ; Carpenter GH; Proctor GB; Nutting CM
    Oral Dis; 2017 Oct; 23(7):990-1000. PubMed ID: 28434191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary gland function in nasopharyngeal carcinoma before and late after intensity-modulated radiotherapy evaluated by dynamic diffusion-weighted MR imaging with gustatory stimulation.
    Shi D; Qian JJ; Fan GH; Shen JK; Tian Y; Xu L
    BMC Oral Health; 2019 Dec; 19(1):288. PubMed ID: 31864328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.